Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8161 to 8175 of 8973 results

  1. Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]

    Discontinued Reference number: GID-TA10779

    Technology appraisal guidance
    Discontinued

  2. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 2 therapies [ID5108]

    Discontinued Reference number: GID-TA11018

    Technology appraisal guidance
    Discontinued

  3. Inotersen for treating hereditary transthyretin amyloidosis (HST9)

    NICE has withdrawn this guidance. Sobi will stop marketing inotersen (Tegsedi) because its no longer available in the UK. Healthcare professionals should discuss alternative treatment options with people currently having inotersen.

    Withdrawn guidance

  4. Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]

    Discontinued Reference number: GID-TA10591

    Technology appraisal guidance
    Discontinued

  5. Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]

    Discontinued Reference number: GID-TA10635

    Technology appraisal guidance
    Discontinued

  6. Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer [ID1169]

    Discontinued Reference number: GID-TA10324

    Technology appraisal guidance
    Discontinued

  7. Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer [ID1335]

    Discontinued Reference number: GID-TA10315

    Technology appraisal guidance
    Discontinued

  8. Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]

    Discontinued Reference number: GID-TA10490

    Technology appraisal guidance
    Discontinued

  9. Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]

    Discontinued Reference number: GID-TA10711

    Technology appraisal guidance
    Discontinued

  10. Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561]

    Discontinued Reference number: GID-TA10442

    Technology appraisal guidance
    Discontinued

  11. Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]

    Discontinued Reference number: GID-TA10687

    Technology appraisal guidance
    Discontinued

  12. Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275

    Discontinued Reference number: GID-TA10375

    Technology appraisal guidance
    Discontinued

  13. Atezolizumab for treating metastatic colorectal cancer after 2 therapies [ID1298]

    Discontinued Reference number: GID-TA10228

    Technology appraisal guidance
    Discontinued

  14. Durvalumab for untreated metastatic non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1331]

    Discontinued Reference number: GID-TA10318

    Technology appraisal guidance
    Discontinued

  15. Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

    Discontinued Reference number: GID-TA10363

    Technology appraisal guidance
    Discontinued